

1 **Continuous quality improvement with a two-step strategy effective for large-scale**

2 **SARS-CoV-2 screening at the Tokyo 2020 Olympic and Paralympic Games**

3 **Short Title:** Quality laboratory improvement for SARS-CoV-2 screening at mass-gathering
4 sporting events

5

6 **Hayato Miyachi**^{1*}, **Satomi Asai**², **Rika Kuroki**³, **Kazuya Omi**⁴, **Chiaki Ikenoue**⁵, and

7 **Satoshi Shimada**⁶

8 ¹ Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, 259-
9 1193, Japan and Faculty of Clinical Laboratory Sciences, Nitobe Bunka College, Tokyo 164-
10 0001 Japan; miyachi@tokai.ac.jp

11 ² Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, 259-
12 1193, Japan; sa@tokai.ac.jp

13 ³ SRL Inc., Tokyo, 107-0052, Japan; rika.kuroki@hugp.com

14 ⁴ SRL Inc., Tokyo, 107-0052, Japan; H.U. Group Research Institute G.K., Tokyo, 197-0833,
15 Japan; and Fujirebio Inc., Tokyo, 107-0052, Japan; kazuya.omi@hugp.com

16 ⁵ Center for Field Epidemic Intelligence, Research and Professional Development, National
17 Institute of Infectious Diseases, Tokyo, 162-8640, Japan; i-chiaki@niid.go.jp

18 ⁶ Department of Eco-Epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki
19 University, Nagasaki, 852–8523, Japan and Center for Emergency Preparedness and
20 Response, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan;
21 satoishimada30@gmail.com

22

23 *Correspondence: miyachi@tokai.ac.jp; Tel.: + 81-3-3381-0121

24

25 **Keywords:** COVID-19; Olympic Games; sporting events; mass gatherings

26 **Abstract**

27

28 The Tokyo 2020 Olympic Games (Games) were held during the height of the coronavirus
29 disease 2019 (COVID-19) pandemic. In order to detect the severe acute respiratory syndrome
30 coronavirus-2 (SARS-CoV-2) early enough to contain the spread as well as to facilitate the
31 timely arrival of athletes at their game venues, all participating athletes up to 14,000 staying
32 in the Olympic Village were screened daily for the infection. Toward this aim, a two-step
33 strategy was adopted comprising screening of self-collected saliva samples using a
34 chemiluminescence enzyme immunoassay followed by confirmatory testing using
35 polymerase chain reaction. The testing system was integrated with an information
36 management system covering all steps. To ensure the accuracy of testing results, rigorous
37 quality assurance measures and monitoring of performance/specimen quality were
38 implemented. The chronological chart analysis was implemented to monitor the holistic
39 process and to give feedback to improve the sampling. Nearly all test results for 418506
40 saliva samples were reported within 12 hours of sample collection, achieving the target mean
41 turnaround time of 150 minutes for confirmatory testing. As a result, athlete activity and
42 performance for the Games were ensured. The chronological chart confirmed that no athletes
43 were retired due to a false-positive result and no infection clusters among athletes were
44 identified. In conclusion, continuous quality improvement in the two-step strategy for the
45 large-scale screening of COVID-19 contributed to the success of the Games during the
46 pandemic. The quality practice, systems, and workflows described here may offer a model for
47 future mass-gathering sporting events during similar major infectious disease epidemics.

48

49 **Introduction**

50 Held in Summer 2021 following a 1-year postponement amid the coronavirus disease
51 2019 (COVID-19) pandemic, the Tokyo 2020 Games faced the challenge of surging COVID-
52 19 rates, with the incidence reaching unprecedented levels both in Tokyo and globally [1].
53 The Tokyo 2020 Infectious Diseases Control Centre organized by the Tokyo Organizing
54 Committee of the Olympic and Paralympic Games (TOCOG) played a vital role in containing
55 the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the
56 Games via the implementation of planned biosafety protocols, including frequent testing for
57 SARS-CoV-2 [2].

58 In order to detect the virus with sufficient time to contain the spread as well as to
59 facilitate the timely arrival of athletes at their game venues, all participating athletes and
60 others staying in the Olympic Village were screened daily for SARS-CoV-2 infection with a
61 two-step strategy comprising screening of self-collected saliva samples using a
62 chemiluminescence enzyme immunoassay (CLEIA) followed by confirmatory testing of
63 saliva and nasopharyngeal swab samples using polymerase chain reaction (PCR) [2,3] instead
64 of PCR screening. Although the “gold standard” of SARS-CoV-2 testing via PCR using NP
65 swab samples is accurate and reliable, results may take 24–48 h to return. Such delays may
66 lead to not only further transmission of disease but can also diminish the daily activity of
67 athletes for training and arrival at the match venue. Furthermore, it requires trained
68 professionals in full protective equipment to collect specimens one person at a time. Solutions
69 to improve the efficiency of mass-screening for SARS-CoV-2 include the replacement of NP
70 swab samples with self-collected saliva thereby eliminating specialized medical personnel
71 and allowing simultaneous parallel sample collection [3]. To monitor in real-time the
72 workflow processes of each individual test, the testing system was integrated with an
73 information management system covering all steps from specimen collection to reporting

74 results. This strategic allocation of PCR tests to cases that were CLEIA-positive or
75 inconclusive not only maintained accuracy but also significantly improved logistical
76 efficiency in administering mass screenings. Notably, PCR testing is associated with a
77 potential risk of false-positive results, which causes unnecessary withdrawal of athletes from
78 the Games. In order to ensure the COVID-19 screening test, we implemented continuous
79 quality improvement through rigorous quality assurance measures, performance/specimen
80 quality monitoring by an internal quality assessment, and a chronological chart analysis for
81 individual cases.

82

83 **Material and methods**

84 **Patient and public involvement**

85

86 The study's design including participants was planned and conducted under requests and the
87 endorsement of the TOCOG according to the regulation and the criteria specified by the
88 Ministry of Health, Labour, and Welfare of Japan. Up to 14,000 athletes and team officials
89 were tested daily for SARS-CoV-2 in order to detect infections early as required by the
90 TOCOG.

91

92 **A two-step large-scale screening strategy**

93 To facilitate the timely arrival of athletes at their game venues, test results had to be
94 available within a 12-hour turnaround time (TAT). For this large-scale screening, a two-step
95 strategy was adopted, instead of PCR screening [2,3]. First, quantitative antigen testing was
96 performed using a quantitative CLEIA with a fully automated instrument (Lumipulse®
97 Presto SARS-CoV-2 Ag, Fujirebio, Tokyo, Japan). The quantitative CLEIA is a high-
98 throughput assay with high sensitivity, specificity, and short TAT, and can provide rapid

99 results as an initial saliva screening test. Positive or inconclusive results were confirmed
100 using a standard PCR test. If the saliva PCR showed positive results, a nasopharyngeal (NP)
101 swab was collected at the athletes' village fever clinic for confirmatory PCR testing using the
102 SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc., Kusatsu, Japan) with
103 instruments such as the QuantStudio5 (Thermo Fisher Scientific K.K., Waltham, MA, USA),
104 LightCycler 96 (Roche Molecular Systems, Inc., Pleasanton, CA), and CFX96 (Bio-Rad
105 Laboratories, Inc., Hercules, CA, USA). Symptomatic participants also underwent PCR
106 testing of NP swabs. The workflow was integrated with an information management system.
107 Self-collected saliva was brought to the reception area by COVID-19 Liaison Officers
108 (CLOs). At the reception department, accreditation ID was linked with the sample ID in the
109 information management system by barcode. Radiofrequency identification (RFID, Toppan
110 Forms Inc., Tokyo, Japan) was incorporated into the information management system for
111 specimens. The laboratory information and reporting system (Neo Polaris and Fukuda System,
112 H.U. Group Research Institute G.K., Tokyo, Japan) allowed for real-time monitoring of the
113 workflow processes of each test, covering the entire process from receipt of the specimen to
114 reporting the result to CLOs in addition to recording the internal laboratory workflow (Figure
115 1).

116 Five laboratories coordinated the conducting of testing for various Olympic Games
117 venues. Quantitative CLEIA and PCR tests were also performed in four laboratories outside
118 the village, located in Kawasaki, Tokyo, Sapporo, and Iwaki.

119

120

121 **Fig 1. Workflow Quality Monitoring.** The workflow was integrated with an information
122 management system. Self-collected saliva was brought to the reception area by COVID-19
123 Liaison Officers (CLOs). The accreditation ID of personnel for the Village was linked with

124 radiofrequency identification and sample ID barcodes. This feedback process was used to
125 communicate with the Tokyo Organizing Committee of the Olympic and Paralympic Games
126 (TOCOG) about re-training of CLOs and TOCOG staff in appropriate collection techniques,
127 including self-sampling of saliva before eating, specimen refrigeration within 24 hours of
128 sampling, and NP swab collection, enabling real-time corrections of the process.

129

130 **Rigorous quality assurance measures**

131 As the Tokyo 2020 Games were an international multi-sport event during a pandemic,
132 quality laboratory practices based on both global and regional perspectives were rigorously
133 implemented [4,5]. Actions taken were based on discussion and consensus during the
134 development of the International Organization for Standardization standard (ISO/TS 5798)
135 for SARS-CoV-2 detection using nucleic acid amplification methods [4]. To maintain the
136 expected performance of SARS-CoV-2 laboratory tests, meticulous quality assurance
137 measures such as personnel training, competency assessments, assay performance
138 evaluations, and internal quality controls based on cycle threshold values, were implemented.
139 The assay performance was monitored and confirmed by a nationwide external quality
140 assessment of SARS-CoV-2 nucleic acid amplification tests in Japan [5].

141

142 **Results**

143 **Test volume and turnaround time**

144 During the Games, all participating athletes up to 14,000 and others staying in the
145 Olympic Village were screened daily for SARS-CoV-2 infection with a two-step strategy
146 comprising screening of self-collected saliva samples using a CLEIA followed by
147 confirmatory testing of saliva and nasopharyngeal swab samples using PCR. Using a testing

148 system integrated with an information management system covering all steps, from specimen
149 collection to reporting of the results, enabled monitoring processes of each testing down to
150 confirmatory test results to be provided. A total of 418,506 saliva samples were tested using
151 the quantitative antigen test. Nearly all tests were reported within 12 hours of sample
152 collection, aligning with the target of a mean TAT of 150 minutes for confirmatory tests.

153

154 **Continuous quality improvement**

155 Quality assurance of tests based on both global and regional perspectives was rigorously
156 implemented. To ensure the entire examination process from sample collection to the results
157 report, we developed and analyzed a chronological chart of cases with positive and
158 inconsistent results, providing a holistic overview of the testing process, confirming test
159 results, and identifying underlying problems including poor specimen quality and false-
160 positive results. Inconsistent results were interpreted and judged whether reasonable as a
161 natural course of infection or suspicious test result due to a possible error in any portion of
162 the testing process.

163 Particularly, sample collection methods could impact the results; the pre-examination
164 process posed a critical challenge for mass screening. CLOs played a crucial role in
165 instructing athletes and team officials in proper self-sampling procedures. However, self-
166 sampling in individual rooms had a risk of poor specimen quality due to suboptimal
167 collection and storage practices. Visual examination of specimens revealed sediments, which
168 caused nonspecific reactions, increasing rates of re-measurement, and prolonged the TAT. To
169 mitigate these nonspecific reactions due to sediments, the phosphate-buffered saline for
170 dilution was changed to a proprietary buffer. We evaluated specimen quality using amylase
171 measurement with CicaLiquid AMY (Kanto Chemical Co., Inc., Tokyo, Japan) on a fully
172 automated analyzer (JCA-BM8040, JEOL Ltd., Tokyo, Japan). A high proportion of

173 specimens showed amylase levels under the reference range, suggesting inappropriate storage
174 of specimens at ambient temperature.

175 In the continuous quality improvement of testing during the Games, continuous
176 monitoring was implemented to identify potential bias, which allowed real-time actionable
177 feedback to the TOCOG. We used this feedback process to communicate with TOCOG
178 regarding the re-training of CLOs and TOCOG staff in appropriate collection techniques
179 including self-sampling of saliva before eating, specimen refrigeration within 24 hours of
180 sampling, and NP swab collection. This enabled real-time corrections in the testing process.
181 As a result, the activity and performance of athletes for daily training and participation in the
182 games were ensured. The chronological chart for the individual test results enabled us to
183 confirm in real-time that there were neither infection clusters identified in athletic teams
184 inside the village or Games venues due to false-negative results, nor unnecessary withdrawal
185 of athletes from the Games due to false-positive results.

186

187 **Limitations**

188 The testing for SARS-CoV-2 detection to detect infections early was performed, according to
189 the regulation and the criteria specified by the Ministry of Health, and Labour in Japan.

190 Ideally, the quality and competence of the laboratory and the reliability of its testing service
191 would be objectively audited and endorsed by the third-party accreditation. However, in

192 Japan, laboratory accreditation under ISO 15189, Medical Laboratories – Requirements for
193 quality and competence [6], applies laboratory tests for medical use but not those for public

194 use such as for SARS-CoV-2 screening tests of participating athletes and others staying in the
195 Olympic village. Thus, the laboratory was not subjected to accreditation under ISO 15189.

196 The operation of laboratories was built and conducted, in alignment with the criteria specified

197 for the central laboratory which had been accredited under ISO 15189 and had a
198 responsibility for the testing for SARS-CoV-2 detection under a contract with TOCOG.

199

200 **Discussion**

201 In order to detect SARS-CoV-2 infections as early as possible and to take measures to
202 prevent further spread, a two-step strategy was adopted to meet the large-scale screening
203 requirements of the event. The integration of a testing system with an information
204 management system covering all steps from specimen collection to reporting of the results
205 enabled confirmatory test results to be provided within 12 hours, achieving our target of a
206 mean TAT of 150 minutes for confirmatory tests. This integration enabled all athletes to keep
207 the daily activity of training prior to the match and participate at the game match venue.

208 The accuracy of testing results can have an impact on the risk of transmission of disease.
209 False-negative results may lead to further transmission of disease. False-positive results
210 would lead to the withdrawal of the athlete from further participation in the games.
211 Considering the Tokyo 2020 Games being an international multi-sport event during a
212 pandemic, quality laboratory practices based on both global and regional perspectives were
213 rigorously implemented. In order to minimize such a risk, we implemented and maintained
214 rigorous quality assurance of the entire process of examination of daily testing for SARS-
215 CoV-2. Quality assurance measures included personnel training, competency assessments,
216 assay performance evaluations, and internal quality controls based on cycle threshold values.
217 In addition to that, the pre-examination process was a critical challenge of mass screening in
218 the event. CLOs instructed athletes and team officials on how to perform self-sampling.
219 However, self-sampling in individual rooms posed a risk of poor specimen quality due to

220 suboptimal collection and storage. In order to monitor the quality of specimens, we adopted
221 visual inspection and measurement of amylase in saliva.

222 This shows that international major sporting events could be held during major infectious
223 disease epidemics comparable to the COVID-19 pandemic without causing spikes in the case
224 numbers [7]. These results support the approach, advocated by the World Health
225 Organization, that responding to and managing the COVID-19 pandemic requires using all
226 available options, including public health and social measures, robust test-and-trace systems,
227 and vaccination [1]. During the early phase of the COVID-19 pandemic, most mass-gathering
228 sports events used PCR testing for infection control, which required an extended TAT for
229 receiving results and enforcing quarantine [8-10]. Furthermore, PCR has a potential risk of
230 false-positive results, which caused unnecessary withdrawal of athletes from the Games. Our
231 experience suggests that continuous quality improvement implemented in the two-step
232 strategy and infection control measures at the Games were successful.

233 The SARS-CoV-2 positivity rate among the 11,417 Olympic and 4,393 Paralympic
234 athletes was 0.03% of the total tests conducted [11]. Notably, the chronological chart for the
235 individual test results enabled us to confirm in real-time that there were neither infection
236 clusters identified in athletic teams inside the village or Games venues due to false-negative
237 results, nor unnecessary withdrawal of athletes from the Games due to false-positive results.

238

239 **Conclusion**

240 In conclusion, continuous quality improvement was implemented in the two-step strategy for
241 large-scale COVID-19 screening and contributed to the success of international major
242 sporting events during the pandemic. The quality practice, systems, and workflows of testing
243 with continuous quality improvement, described in this report could serve as a model for
244 future mass-gathering sporting events during similar major infectious disease epidemics.

245

246 **Author Contributions:** Conceptualization and design, H.M., S.A., R.K., K.O., C.I., and S.S.;
247 material preparation, data collection and analysis, H.M., R.K., and K.O., and S.S.; writing—
248 review and editing, H.M., S.A., C.I., and S.S. All authors commented on previous versions of
249 the manuscript. All authors read and approved the final manuscript.

250 **Institutional Review Board Statement:** Ethical review and approval were waived for this
251 study due to the Act on the Prevention of Infectious Diseases and Medical Care for Patients
252 with Infectious Diseases (the Infectious Diseases Control Law) in Japan.

253 **Informed Consent Statement:** Patient consent was waived due to the Act on the Prevention
254 of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the Infectious
255 Diseases Control Law) in Japan.

256 **Data Availability Statement:** The data that support the findings of this study are available
257 from the corresponding author upon reasonable request.

258 **Acknowledgments:** We would like to thank the Tokyo 2020 Organizing Committee. The
259 findings and conclusions in this report are those of the authors and do not necessarily
260 represent the official position of the Tokyo 2020 Organizing Committee. The Tokyo 2020
261 Organizing Committee does not endorse any commercial products or services.

262

263 **References**

- 264 1. World Health Organization (2020). Rolling updates on coronavirus disease (COVID-
265 19). Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
266 2019/events-as-they-happen (Accessed on 27 Nov 2023).
- 267 2. Shimada S, Ikenoue C, Iwashita Y, Miyamoto T. Contributions of the Tokyo 2020
268 Infectious Diseases Control Centre in curbing SARS-CoV-2 spread during the
269 Olympic and Paralympic Games. *Br J Sports Med.* 2023;57:6-7. doi:
270 10.1136/bjsports-2022-105691.
- 271 3. Yokota I, Shane PY, Teshima T. Logistic advantage of two-step screening strategy for
272 SARS-CoV-2 at airport quarantine. *Travel Med Infect Dis.* 2021;43:102127. doi:
273 10.1016/j.tmaid.2021.102127.
- 274 4. International Organization for Standardization. ISO/TS 5798; 2022. In vitro
275 diagnostic test systems – Requirements and recommendations for detection of severe
276 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid
277 amplification methods. Available from: <https://www.iso.org/standard/81712.html>
278 (Accessed on 27 Nov 2023).
- 279 5. Asai S, Seki A, Akai Y, Tazawa H, Kakizoe H, Ravzanaadil MA, et al. Nationwide
280 external quality assessment of SARS-CoV-2 nucleic acid amplification tests in Japan.
281 *Int J Infect Dis.* 2022;115:86-92. doi: 10.1016/j.ijid.2021.11.022.
- 282
- 283 6. Zhang Y, Ai J, Bao J, Zhang W. Lessons learned from the COVID-19 control strategy
284 of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics.
285 *Emerg Microbes Infect.* 2022;11:1711-1716. doi: 10.1080/22221751.2022.2090859.
- 286 7. ISO 15189:2022. Medical laboratories — Requirements for quality and competence
287 <https://www.iso.org/standard/76677.html>

- 288 8. Burke P. Tokyo 2020 did not result in increased COVID-19 cases in Japan IOC
289 claims citing study. 31 Dec 2021.
290 [https://www.insidethegames.biz/articles/1117299/tokyo-2020-covid-cases-contained-](https://www.insidethegames.biz/articles/1117299/tokyo-2020-covid-cases-contained-ioc)
291 ioc
- 292 9. Nishino T Obara K Nishida Y et al. Large-scale international volleyball competition
293 in "bubble" under the COVID-19 pandemic. *Asia Pac J Sports Med Arthrosc Rehabil*
294 *Technol.* 2022;7:9–12. doi: 10.1016/j.asmart.2021.12.001.
- 295 10. Caniza H Forriol F Pangrazio O et al. Safety of international professional sports
296 competitions during the COVID-19 pandemic: the association football experience.
297 *Sports Med.* 2023;53:765–768. doi: 10.1007/s40279-022-01763-3. Epub 2022 Sep 27.
298 PMID: 36167919
- 299 11. The Tokyo Organising Committee of the Olympic and Paralympic Games. COVID-
300 19 positive case list. Available from: [https://olympics.com/tokyo-](https://olympics.com/tokyo-2020/en/notices/covid-19-positive-case-list)
301 [2020/en/notices/covid-19-positive- case-list](https://olympics.com/tokyo-2020/en/notices/covid-19-positive-case-list) (Accessed on 27 Nov 2023).

